Education
About Us
Working with TipRanks
Follow Us
Recce Pharmaceuticals Ltd. (AU:RCE)
:RCE
Total Valuation
Recce Pharmaceuticals Ltd. has a market cap or net worth of AU$160.50M. The enterprise value is AU$70.42M.
Market CapAU$160.50M
Enterprise ValueAU$70.42M
Share Statistics
Recce Pharmaceuticals Ltd. has 289,183,400 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding289,183,400
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Recce Pharmaceuticals Ltd.’s return on equity (ROE) is 7.02 and return on invested capital (ROIC) is -195.20%.
Return on Equity (ROE)7.02
Return on Assets (ROA)-1.73
Return on Invested Capital (ROIC)-195.20%
Return on Capital Employed (ROCE)-3.64
Revenue Per Employee10.00T>
Profits Per Employee―
Employee Count―
Asset Turnover0.60
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Recce Pharmaceuticals Ltd. is ―. Recce Pharmaceuticals Ltd.’s PEG ratio is 0.34.
PE Ratio―
PS Ratio9.15
PB Ratio-22.52
Price to Fair Value-22.52
Price to FCF-3.36
Price to Operating Cash Flow-4.97
PEG Ratio0.34
Income Statement
In the last 12 months, Recce Pharmaceuticals Ltd. had revenue of 7.51M and earned -21.43M in profits. Earnings per share was -0.09.
Revenue7.51M
Gross Profit-2.94M
Operating Income-22.88M
Pretax Income-21.43M
Net Income-21.43M
EBITDA-20.33M
Earnings Per Share (EPS)-0.09
Cash Flow
In the last 12 months, operating cash flow was -20.44M and capital expenditures -26.35K, giving a free cash flow of -20.47M billion.
Operating Cash Flow-20.44M
Free Cash Flow-20.47M
Free Cash Flow per Share-0.07
Dividends & Yields
Recce Pharmaceuticals Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.84
52-Week Price Change18.37%
50-Day Moving Average0.45
200-Day Moving Average0.38
Relative Strength Index (RSI)67.98
Average Volume (3m)135.90K
Important Dates
Recce Pharmaceuticals Ltd. upcoming earnings date is Mar 2, 2026, TBA (Confirmed).
Last Earnings DateAug 29, 2025
Next Earnings DateMar 2, 2026
Ex-Dividend Date―
Financial Position
Recce Pharmaceuticals Ltd. as a current ratio of 1.86, with Debt / Equity ratio of -352.83%
Current Ratio1.86
Quick Ratio1.86
Debt to Market Cap0.15
Net Debt to EBITDA-0.02
Interest Coverage Ratio-18.16
Taxes
In the past 12 months, Recce Pharmaceuticals Ltd. has paid -6.74M in taxes.
Income Tax-6.74M
Effective Tax Rate0.31
Enterprise Valuation
Recce Pharmaceuticals Ltd. EV to EBITDA ratio is -3.40, with an EV/FCF ratio of -3.37.
EV to Sales9.19
EV to EBITDA-3.40
EV to Free Cash Flow-3.37
EV to Operating Cash Flow-3.38
Balance Sheet
Recce Pharmaceuticals Ltd. has AU$10.45M in cash and marketable securities with AU$10.77M in debt, giving a net cash position of -AU$319.44K billion.
Cash & Marketable SecuritiesAU$10.45M
Total DebtAU$10.77M
Net Cash-AU$319.44K
Net Cash Per Share>-AU$0.01
Tangible Book Value Per Share-AU$0.01
Margins
Gross margin is -39.12%, with operating margin of -304.71%, and net profit margin of -285.37%.
Gross Margin-39.12%
Operating Margin-304.71%
Pretax Margin-285.37%
Net Profit Margin-285.37%
EBITDA Margin-270.81%
EBIT Margin-271.76%
Analyst Forecast
The average price target for Recce Pharmaceuticals Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast0.66%